Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{200067,
        author = {Madhavan.S and Pazhanivel.G and R.Kalaivani and Nepolean.R},
        title = {Pulmonary Arterial Hypertension},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {12},
        pages = {753-755},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=200067},
        abstract = {Pulmonary arterial hypertension (PAH) is a chronic, progressive, and life-threatening disorder characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, ultimately leading to right ventricular failure and death if untreated. Over the past two decades, substantial advances have been made in understanding the molecular and cellular mechanisms underlying PAH, resulting in improved diagnostic strategies and targeted therapies. Despite these advancements, PAH remains incurable and is associated with significant morbidity and mortality. This assignment provides a comprehensive overview of PAH, including its epidemiology, pathophysiology, classification, clinical presentation, diagnostic evaluation, treatment modalities, and emerging research trends.},
        keywords = {},
        month = {May},
        }